|
AstraZeneca and Rigel strike asthma deal worth up to $100M
FierceBiotech The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma. AstraZeneca And Rigel Sign Worldwide License Agreement For A … AstraZeneca, Rigel to Develop Asthma Treatment Rigel, AstraZeneca strike potential $100M asthma drug deal |
View full post on asthma – Google News